Please login to the form below

Not currently logged in
Email:
Password:

CLL

This page shows the latest CLL news and features for those working in and with pharma, biotech and healthcare.

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

It is looking at the safety of the antibody in combination of Gilead’s Zydelig (idelalisib) or Roche/AbbVie’s Venclexta (venetoclax) in patients with chronic lymphocytic leukaemia (CLL) or small

Latest news

  • Venclexta plus Gazyva approval adds to non-chemo options in CLL Venclexta plus Gazyva approval adds to non-chemo options in CLL

    The drug is one of a new generation of CLL treatments now expanding into frontline use. ... The company recently announced positive phase 3 data of its challenger  Calquence(acalabrutinib) in previously-treated CLL, with the trial stopped early because

  • New data backs Merck’s segue into MS with BTK inhibitor New data backs Merck’s segue into MS with BTK inhibitor

    lymphocytic leukaemia (CLL) would be halted early after positive results. ... The ASCEND study is the first of two phase 3 CLL trials with Calquence expected to read out in 2019, and approval in this indication would expand the market for the

  • Janssen looks to expand Darzalex in Europe Janssen looks to expand Darzalex in Europe

    The drug is approved in CLL, but not yet approved for use in multiple myeloma, however the FDA just issued a warning after a review of its phase 3 BELLINI trial

  • Roche, AbbVie hit by clinical hold for Venclexta in myeloma Roche, AbbVie hit by clinical hold for Venclexta in myeloma

    The drug has been approved for chronic lymphocytic leukaemia (CLL) since 2016 and picked up a second indication in acute myeloid leukaemia (AML) last year, but analyst Steve Scala at Cowen ... An approval in first-line CLL should help accelerate growth,

  • Roche files Venclexta plus Gazyva in CLL Roche files Venclexta plus Gazyva in CLL

    Venclexta (Venclyxto outside the US) is co-marketed by AbbVie and Roche and if approved, the combination with Gazyva in first line treatment of CLL could see its use expanded greatly. ... The drug is one of a new generation of CLL treatments now

More from news
Approximately 14 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Asset acquisition - products. 121. †Eagle Pharmaceuticals/ Teva. EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL. ... CLL, chronic lymphocytic leukaemia;  NHL, indolent non-Hodgkin lymphoma.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3). ... Abbreviations. ImmTacs = Immune mobilising mTCR against cancer. CLL = chronic lymphocytic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics